Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche Snaps Up Bay Area’s Adheron in $580 Million Deal

Swiss-based Roche (RHHBY) acquired San Francisco-based Adheron Therapeutics for up to $580 million today.   Adheron focuses on technology that disrupts cell adhesion, which has potential applications for a variety of diseases. Its focus is Cadherin-11 (Cad-11), a surface protein found on fibroblasts in the skin and lungs, and fibroblast-like synoviocytes (FLS) found in the […]

Read More »

AbbVie scraps Galapagos deal to focus on own arthritis drug

AbbVie Inc said its experimental drug improved symptoms of rheumatoid arthritis in mid-stage studies and scrapped plans to buy rights to a similar treatment from Belgium’s Galapagos NV. Galapagos shares were down 27 percent at 40.20 euros in Amsterdam. AbbVie shares rose 2 percent to $57.66 in early trading on Friday. Analysts said the drug’s […]

Read More »

Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology     September 24, 2015 05:00 PM Eastern Daylight Time   DARMSTADT, Germany & NEW YORK–(BUSINESS WIRE)–As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the […]

Read More »

Nestle pushes further into medicine with planned Alzheimer’s test

ZURICH (Reuters) – Food group Nestle has taken a further step into the medicine business by signing a research collaboration agreement with a Swiss biotech company to develop an Alzheimer’s disease diagnostic test. Nestle’s second medical deal in a week underscores the commitment by the world’s largest packaged food company to the faster-growing, more profitable […]

Read More »

Craig Venter’s company in deal for whole exome tests at new low cost

A company formed by genome pioneer Craig Venter will offer clients of a South Africa-based insurance company whole exome sequencing –sequencing all protein-making genes in the human genome – at a price that marks yet another dramatic decline in the cost of gene sequencing, the two companies said on Tuesday. Venter’s company, Human Longevity Inc, […]

Read More »

Perrigo recommends shareholders reject Mylan’s tender offer

Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV’s unsolicited $27 billion tender offer, saying it substantially undervalued the company. Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday. It has said it would take control if more than […]

Read More »

World’s biggest private biotech Intarcia in no rush to list

Intarcia Therapeutics, with an enviable cash pile to fund development of its matchstick-size implantable drug-delivery pump for diabetes, is happy to sit out the current initial public offering (IPO) boom. The Boston-based group clinched a royalty-based financing deal in April valuing the company at $5.5 billion, more than any other unlisted emerging biotechnology business in […]

Read More »

Nestle enters agreement to develop ulcerative colitis therapy

Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday. Nestle Health Science intends to develop an add-on therapy to an existing one that is commonly used but with […]

Read More »

Dental supply maker Dentsply to buy Sirona in $5.56 billion deal

Dentsply International Inc (XRAY.O) said on Tuesday it would merge with peer Sirona Dental Systems Inc (SIRO.O) in a $5.56 billion all-stock deal, creating the world’s largest dental equipment maker. The deal will combine Dentsply’s single-use dental supplies, such as paste and sealants, with Sirona’s advanced technology equipment, such as imaging systems and instruments. “There […]

Read More »

Roche says biotech bubble pushes midsize buys out of reach

The biotechnology sector is in a “bubble”, pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday.   “I think this bubble will burst at some point,” Severin Schwan told Reuters in an interview during a visit to London. The Swiss company […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom